CureVac COVID vaccine let-down spotlights mRNA design challenges
Elie Dolgin • June 18, 2021
Scientists are searching for explanations to disappointing final-stage trial results. These insights could help guide the future development of mRNA vaccines.
Two vaccines made using messenger RNA (mRNA) have proved spectacularly successful at warding off COVID-19, but a third mRNA-based candidate has flopped in a final-stage trial, according to an initial report released this week.
Researchers are now asking why — and some think that choices about the type of mRNA chemistry used might be to blame. Any insight could help to guide the future design of mRNA vaccines against COVID-19 or other diseases.
Continue reading at Nature.
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.
Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.